Mattias Ekman

Summary

Affiliation: AstraZeneca R and D

Publications

  1. doi request reprint The societal cost of bipolar disorder in Sweden
    Mattias Ekman
    OptumInsight, Stockholm, Sweden
    Soc Psychiatry Psychiatr Epidemiol 48:1601-10. 2013
  2. ncbi request reprint The societal cost of depression: evidence from 10,000 Swedish patients in psychiatric care
    M Ekman
    OptumInsight, Stockholm, Sweden
    J Affect Disord 150:790-7. 2013
  3. ncbi request reprint The societal cost of schizophrenia in Sweden
    Mattias Ekman
    Health Economics and Outcomes Research, OptumInsight, Stockholm, Sweden
    J Ment Health Policy Econ 16:13-25. 2013
  4. doi request reprint Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode
    Mattias Ekman
    OptumInsight, Stockholm, Sweden
    Pharmacoeconomics 30:513-30. 2012
  5. ncbi request reprint Health-related quality of life measured with EQ-5D in patients treated for depression in primary care
    Patrik Sobocki
    Karolinska Institutet, Stockholm, Sweden
    Value Health 10:153-60. 2007
  6. ncbi request reprint Model to assess the cost-effectiveness of new treatments for depression
    Patrik Sobocki
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet and European Health Economics AB, Stockholm, Sweden
    Int J Technol Assess Health Care 22:469-77. 2006
  7. ncbi request reprint Health utilities in mild cognitive impairment and dementia: a population study in Sweden
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:649-55. 2007
  8. ncbi request reprint Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Scand Cardiovasc J 40:17-24. 2006
  9. ncbi request reprint Burden of illness of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Spine (Phila Pa 1976) 30:1777-85. 2005
  10. ncbi request reprint Proton therapy of cancer: potential clinical advantages and cost-effectiveness
    Jonas Lundkvist
    Stockholm Health Economics, Stockholm, Sweden
    Acta Oncol 44:850-61. 2005

Detail Information

Publications11

  1. doi request reprint The societal cost of bipolar disorder in Sweden
    Mattias Ekman
    OptumInsight, Stockholm, Sweden
    Soc Psychiatry Psychiatr Epidemiol 48:1601-10. 2013
    ..The purpose of this study was to estimate the societal cost of bipolar disorder and to relate costs to disease severity, depressive episodes, hospitalisation and patient functioning...
  2. ncbi request reprint The societal cost of depression: evidence from 10,000 Swedish patients in psychiatric care
    M Ekman
    OptumInsight, Stockholm, Sweden
    J Affect Disord 150:790-7. 2013
    ..The objectives of this study were to estimate the societal per-patient cost of depression in specialized psychiatric care in Sweden, and to relate costs to disease severity, depressive episodes, hospitalization, and patient functioning...
  3. ncbi request reprint The societal cost of schizophrenia in Sweden
    Mattias Ekman
    Health Economics and Outcomes Research, OptumInsight, Stockholm, Sweden
    J Ment Health Policy Econ 16:13-25. 2013
    ..Existing cost estimates for Sweden, however, are based on relatively small patient populations and need to be confirmed in a large register-based study...
  4. doi request reprint Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode
    Mattias Ekman
    OptumInsight, Stockholm, Sweden
    Pharmacoeconomics 30:513-30. 2012
    ....
  5. ncbi request reprint Health-related quality of life measured with EQ-5D in patients treated for depression in primary care
    Patrik Sobocki
    Karolinska Institutet, Stockholm, Sweden
    Value Health 10:153-60. 2007
    ..The objective of the present study was to assess the impact of depression on patients' health-related quality of life (HRQL) with the EQ-5D instrument over 6 months while on antidepressant treatment...
  6. ncbi request reprint Model to assess the cost-effectiveness of new treatments for depression
    Patrik Sobocki
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet and European Health Economics AB, Stockholm, Sweden
    Int J Technol Assess Health Care 22:469-77. 2006
    ..The objective of this study was to develop a model to assess the cost-effectiveness of a new treatment for patients with depression...
  7. ncbi request reprint Health utilities in mild cognitive impairment and dementia: a population study in Sweden
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:649-55. 2007
    ..To collect new primary data on community-based health utilities (time trade-off values) in different stages of mild cognitive impairment and dementia from a general population sample...
  8. ncbi request reprint Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Scand Cardiovasc J 40:17-24. 2006
    ..To analyse the cost-effectiveness of Taxus compared to a bare-metal stent in patients with coronary artery disease in the Swedish healthcare setting...
  9. ncbi request reprint Burden of illness of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Spine (Phila Pa 1976) 30:1777-85. 2005
    ..Cross-sectional survey of patients with chronic low back pain in primary care setting...
  10. ncbi request reprint Proton therapy of cancer: potential clinical advantages and cost-effectiveness
    Jonas Lundkvist
    Stockholm Health Economics, Stockholm, Sweden
    Acta Oncol 44:850-61. 2005
    ..8 million. Investment in a proton facility may thus be cost-effective. The results must be interpreted with caution, since there is a lack of data, and consequently large uncertainties in the assumptions used...
  11. doi request reprint Cost of disorders of the brain in Europe 2010
    Anders Gustavsson
    OptumInsight, Stockholm, Sweden
    Eur Neuropsychopharmacol 21:718-79. 2011
    ..We therefore present much improved cost estimates. Our revised estimates also now include the new EU member states, and hence a population of 514 million people...